Investors seeking biotechnology exposure frequently weigh two of the largest and most liquid funds in the category: the iShares Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI). Although both are passive ETFs (exchange-traded funds) targeting U.S. biotech, they are not direct substitutes. Their weighting schemes create materially different risk and return profiles, making this ETF comparison especially relevant amid shifting interest-rate expectations, robust deal activity, and an active FDA (Food and Drug Administration) approval calendar. Understanding their structural differences helps investors align sector exposure with their own risk tolerance and investment horizon.
Launched in 2001 by BlackRock, IBB seeks to track a modified market-capitalization-weighted index of U.S.-listed biotechnology and life sciences companies — historically the Nasdaq Biotechnology Index. With roughly 250 holdings and well over $10 billion in AUM (assets under management), it is one of the most established and liquid biotech vehicles available. Its expense ratio is 0.44%.
Because it weights by market capitalization, IBB tilts heavily toward established large-cap names. Top holdings include GILD (Gilead Sciences), AMGN (Amgen), VRTX (Vertex Pharmaceuticals), REGN (Regeneron Pharmaceuticals), MRNA (Moderna), and NTRA (Natera). Sector allocation is concentrated in biotechnology (roughly 82%), with a meaningful life sciences tools and services sleeve (about 15%) and a small pharmaceuticals allocation. This large-cap bias historically produces lower volatility than broader, equal-weight biotech peers.
Launched in 2006 by State Street Global Advisors, XBI tracks the S&P Biotechnology Select Industry Index using a modified equal-weight methodology. This approach rebalances regularly to keep each constituent near an equal weight, preventing any single stock from dominating the portfolio. With roughly 130–170 holdings and a similar multi-billion-dollar asset base, XBI also offers strong liquidity, yet its expense ratio of 0.35% is lower than IBB's.
Equal weighting shifts XBI's center of gravity toward small- and mid-cap, often clinical-stage, companies. Representative top holdings include MRNA (Moderna), NTRA (Natera), TWST (Twist Bioscience), HALO (Halozyme Therapeutics), ABBV (AbbVie), and IOVA (Iovance Biotherapeutics), each typically weighing under 3%. With the top 10 holdings accounting for only about 15% of assets, XBI provides broader single-stock diversification but also greater exposure to smaller, higher-beta names and correspondingly higher volatility.
Both funds operate within a healthcare sub-sector defined by binary clinical outcomes, heavy R&D (research and development) spending, and regulatory dependency. Several durable themes shape the current environment. Capital flows into biotech have been supported by expectations for lower interest rates, which improve the relative appeal of long-duration, cash-burning innovators. M&A remains a central catalyst, as large pharmaceutical companies replenish pipelines through acquisitions of smaller developers. Innovation in areas such as gene editing, antibody-drug conjugates, and obesity and oncology therapies continues to attract attention, while FDA approval cycles and drug-pricing policy debates introduce periodic risk. These forces affect both ETFs but tend to resonate more strongly with XBI's small/mid-cap, deal-sensitive composition.
Over recent market cycles, XBI's equal-weight, small/mid-cap tilt has allowed it to capture significantly stronger upside than IBB when risk appetite improved, capital flowed toward clinical-stage names, and M&A activity accelerated. IBB, by contrast, has delivered more measured fund performance, cushioned by the steadier earnings of large-cap anchors such as AMGN and GILD. This relative positioning highlights a key trade-off: XBI offers higher beta and greater sensitivity to sector rotation and rate expectations, while IBB provides a more defensive, quality-tilted form of sector exposure. In risk-off stretches, XBI's higher volatility and small-cap leverage have historically translated into deeper drawdowns, whereas IBB's concentration in established franchises has tended to dampen downside.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trend strength, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending names, and breakout candidates far more efficiently than manual screening, supporting faster and more systematic relative-positioning decisions. Explore the AI Screener to refine your own ETF comparison and uncover actionable opportunities.
Based on observable structural factors, Tickeron's AI would likely favor XBI in the current environment. Its equal-weight design, broader diversification, lower 0.35% expense ratio, and greater sensitivity to sector momentum and M&A activity position it to capture upside when risk appetite for small- and mid-cap biotech is firm. However, this preference is probabilistic rather than absolute: IBB remains the stronger candidate for investors prioritizing stability, large-cap quality, and lower volatility. The optimal choice ultimately depends on an investor's risk tolerance, time horizon, and view on whether the current biotech upcycle continues to favor earlier-stage, deal-sensitive names.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for IBB moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 56 of the 62 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In 83 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
IBB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
IBB moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IBB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 276 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 219 of 244 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Stochastic Oscillator for XBI moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 66 similar instances where the indicator exited the overbought zone. In 63 of the 66 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 83 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 46 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
| IBB | XBI | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 89% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 86% | 3 days ago 84% |
| TrendWeek ODDS (%) | 3 days ago 85% | 3 days ago 88% |
| TrendMonth ODDS (%) | 3 days ago 87% | 3 days ago 90% |
| Advances ODDS (%) | 7 days ago 85% | 7 days ago 90% |
| Declines ODDS (%) | 3 days ago 83% | 3 days ago 89% |
| BollingerBands ODDS (%) | 3 days ago 90% | 4 days ago 90% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 86% |
A.I.dvisor indicates that over the last year, IBB has been closely correlated with VRTX. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if IBB jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To IBB | 1D Price Change % | ||
|---|---|---|---|---|
| IBB | 100% | -0.44% | ||
| VRTX - IBB | 67% Closely correlated | -0.74% | ||
| CRSP - IBB | 65% Loosely correlated | -0.89% | ||
| DYN - IBB | 63% Loosely correlated | +0.88% | ||
| EDIT - IBB | 63% Loosely correlated | +1.40% | ||
| BCYC - IBB | 62% Loosely correlated | -2.32% | ||
More | ||||
A.I.dvisor indicates that over the last year, XBI has been loosely correlated with RCUS. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To XBI | 1D Price Change % | ||
|---|---|---|---|---|
| XBI | 100% | -0.43% | ||
| RCUS - XBI | 59% Loosely correlated | -1.91% | ||
| VYGR - XBI | 59% Loosely correlated | +1.76% | ||
| LYEL - XBI | 57% Loosely correlated | -8.57% | ||
| LGND - XBI | 56% Loosely correlated | -2.37% | ||
| MGNX - XBI | 55% Loosely correlated | -3.93% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SSPY | 102.46 | 0.23 | +0.23% |
| Stratified LargeCap Index ETF (SSPY) | |||
| LDDR | 73.86 | -0.02 | -0.03% |
| Stone Ridge Trust Stone Ridge 2035 Term Income ETF | |||
| CGSD | 25.29 | -0.01 | -0.04% |
| Capital Group Short Duration Income ETF (CGSD) | |||
| DFEB | 51.73 | -0.08 | -0.15% |
| FT Vest U.S. Equity Deep Buffer ETF - February (DFEB) | |||
| NLSI | 57.15 | -0.19 | -0.34% |
| NEOS Long/Short Equity Income ETF (NLSI) | |||